Product Detail

loading

Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 2778223-51-9, methyl (1s,4s)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyra- zol-3-yl)amino)pyrimidin-2-yl)cyclohexane-1-carboxylate

  • 2778223-51-9

  • C18H25N5O3

  • 359.42

  • 1.25±0.1

  • >98.0% (HPLC); >98.0% (chiral)

  • White Solid

  • Non-small-cell lung cancer

  • Pralsetinib

  • 4/3/2039 (Pralsetinib)

  • RTKs

  • N

  • 2-4 weeks

  • 2022

  • ISO 9001

  • CDMO

Availability:

Product Description

Drug  Background Pralsetinib - a groundbreaking drug designed to revolutionize patient care. With its unparalleled efficacy and unrivaled precision, Pralsetinib unlocks new possibilities in oncology treatment. Its targeted therapy approach, specifically tailored to address genetic alterations in non-small cell lung cancer, provides a beacon of hope for patients and pharmaceutical companies alike. Offering swift response rates and manageable adverse effects, Pralsetinib holds immense potential to optimize treatment outcomes and redefine the future of cancer therapeutics. Join the vanguard of innovation and consider Pralsetinib for your portfolio.

Previous: 
Next: